Action of dopamine on the human iris
- 8 November 1969
- Vol. 4 (5679), 333-335
- https://doi.org/10.1136/bmj.4.5679.333
Abstract
Dopamine eye drops produce marked dilatation of the pupil in man. This mydriatic effect is inhibited by pretreatment with guanethidine. It is therefore concluded that dopamine acts indirectly via adrenergic nerve endings, rather than exerting a direct effect on adrenergic receptors in the dilator pupillae muscle. In this respect dopamine resembles the phenyl-alkylamines, such as tyramine, rather than the catecholamines, adrenaline and noradrenaline. If dopamine acts by releasing noradrenaline from adrenergic nerve endings, high concentrations of dopamine could lead to depletion of noradrenaline stores, since synthesis might be unable to keep pace with release. This could be the explantion for the orthostatic hypotension found in patients taking L-dopa for Parkinsonism.Keywords
This publication has 9 references indexed in Scilit:
- L-DOPA IN POSTENCEPHALITIC PARKINSONISMThe Lancet, 1969
- Modification of Parkinsonism — Chronic Treatment with L-DopaNew England Journal of Medicine, 1969
- Ephedrine mydriasis in hypertension and the response to treatmentClinical Pharmacology & Therapeutics, 1969
- Alpha receptor blockade by thymoxamine in the human eyeClinical Pharmacology & Therapeutics, 1968
- Long-term trial of local guanethidine in treatment of eye signs of thyroid dysfunction and idiopathic lid retraction.BMJ, 1967
- ADRENERGIC BLOCKADE AND THE EYE SIGNS OF THYROTOXICOSISThe Lancet, 1966
- Dopamine (3-hydroxytyramine) and brain function.1966
- THE RELATIONSHIP BETWEEN THE MYDRIATIC ACTION OF EPHEDRINE AND THE COLOUR OF THE IRISBritish Journal of Ophthalmology, 1965
- NOREPINEPHRINE SYNTHESIS AND RELEASE IN VIVO MEDIATED BY 3,4-DIHYDROXYPHENETHYLAMINE1963